Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Jasper Therapeutics, Inc. (JSPR) had Return on Tangible Equity of -115.56% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-71.27M |
|
-- |
|
-- |
|
$76.24M |
|
$-76.24M |
|
$4.97M |
|
$-71.27M |
|
$-71.27M |
|
$-71.27M |
|
$-71.27M |
|
$-71.27M |
|
$-71.27M |
|
$-76.24M |
|
$-74.87M |
|
14.59M |
|
14.59M |
|
$-4.89 |
|
$-4.89 |
|
| Balance Sheet Financials | |
$75.81M |
|
$1.88M |
|
$4.09M |
|
$79.90M |
|
$15.24M |
|
-- |
|
$2.99M |
|
$18.23M |
|
$61.67M |
|
$61.67M |
|
$61.67M |
|
15.02M |
|
| Cash Flow Statement Financials | |
$-62.60M |
|
$-0.53M |
|
$47.88M |
|
$87.30M |
|
$72.05M |
|
$-15.25M |
|
$6.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-63.13M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-115.56% |
|
|
Return on Tangible Equity |
-115.56% |
-89.20% |
|
-115.56% |
|
$4.11 |
|
$-4.33 |
|
$-4.29 |
|